Morgan Stanley Organogenesis Holdings Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Organogenesis Holdings Inc. stock. As of the latest transaction made, Morgan Stanley holds 12,055,947 shares of ORGO stock, worth $54.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,055,947

Previous 12,115,975 0.5%

Holding current value

$54.6 Million

Previous $52.3 Million 15.7%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$2.66 - $5.34 $159,674 - $320,549	-60,028 Reduced 0.5%	12,055,947 $44.1 Million
Q1 2025 May 15, 2025	BUY	$2.89 - $6.21 $824,800 - $1.77 Million	285,398 Added 2.41%	12,115,975 $52.3 Million
Q4 2024 Feb 14, 2025	SELL	$2.77 - $4.43 $385,464 - $616,465	-139,157 Reduced 1.16%	11,830,577 $37.9 Million
Q3 2024 May 14, 2025	BUY	$2.42 - $3.24 $952,693 - $1.28 Million	393,675 Added 3.4%	11,969,734 $34.2 Million
Q3 2024 Nov 14, 2024	BUY	$2.42 - $3.24 $952,693 - $1.28 Million	393,675 Added 3.4%	11,969,734 $34.2 Million
Q2 2024 May 14, 2025	SELL	$2.28 - $3.03 $580,301 - $771,189	-254,518 Reduced 2.15%	11,576,059 $32.4 Million
Q2 2024 Oct 17, 2024	BUY	$2.28 - $3.03 $109,510 - $145,533	48,031 Added 0.42%	11,576,059 $32.4 Million
Q2 2024 Aug 14, 2024	BUY	$2.28 - $3.03 $109,510 - $145,533	48,031 Added 0.42%	11,576,059 $32.4 Million
Q1 2024 Oct 17, 2024	SELL	$2.61 - $4.49 $125,360 - $215,659	-48,031 Reduced 0.41%	11,528,028 $32.7 Million
Q1 2024 Aug 16, 2024	SELL	$2.61 - $4.49 $4.83 Million - $8.31 Million	-1,849,728 Reduced 13.83%	11,528,028 $32.7 Million
Q1 2024 May 15, 2024	SELL	$2.61 - $4.49 $4.83 Million - $8.31 Million	-1,849,728 Reduced 13.83%	11,528,028 $32.7 Million
Q4 2023 Aug 16, 2024	BUY	$1.97 - $4.21 $3.55 Million - $7.59 Million	1,801,697 Added 15.56%	13,377,756 $54.7 Million
Q4 2023 Feb 13, 2024	BUY	$1.97 - $4.21 $12.7 Million - $27.1 Million	6,437,212 Added 92.75%	13,377,756 $54.7 Million
Q3 2023 Nov 15, 2023	BUY	$2.34 - $4.43 $14 Million - $26.6 Million	5,994,373 Added 633.54%	6,940,544 $22.1 Million
Q2 2023 Aug 14, 2023	BUY	$1.9 - $4.3 $802,088 - $1.82 Million	422,152 Added 80.56%	946,171 $3.14 Million
Q1 2023 May 15, 2023	SELL	$1.89 - $2.93 $2.75 Million - $4.26 Million	-1,455,098 Reduced 73.52%	524,019 $1.12 Million
Q4 2022 Feb 14, 2023	SELL	$2.48 - $3.43 $3.16 Million - $4.37 Million	-1,272,952 Reduced 39.14%	1,979,117 $5.32 Million
Q3 2022 Nov 14, 2022	SELL	$3.14 - $6.43 $823,976 - $1.69 Million	-262,413 Reduced 7.47%	3,252,069 $10.5 Million
Q2 2022 Oct 27, 2022	BUY	$4.74 - $8.15 $2.44 Million - $4.2 Million	515,655 Added 17.2%	3,514,482 $17.2 Million
Q2 2022 Aug 15, 2022	BUY	$4.74 - $8.15 $2.44 Million - $4.2 Million	515,655 Added 17.2%	3,514,482 $17.2 Million
Q1 2022 Oct 27, 2022	SELL	$6.47 - $9.57 $3.34 Million - $4.93 Million	-515,655 Reduced 14.67%	2,998,827 $22.9 Million
Q1 2022 May 13, 2022	BUY	$6.47 - $9.57 $8.63 Million - $12.8 Million	1,333,720 Added 80.1%	2,998,827 $22.9 Million
Q4 2021 Feb 14, 2022	BUY	$9.02 - $13.5 $2.15 Million - $3.22 Million	238,330 Added 16.7%	1,665,107 $15.4 Million
Q3 2021 Nov 15, 2021	BUY	$13.71 - $17.18 $19.6 Million - $24.5 Million	1,426,777 New	1,426,777 $20.3 Million

Others Institutions Holding ORGO

# of Institutions

123

Shares Held

69.9M

Call Options Held

15.1K

Put Options Held

View Full List

About Organogenesis Holdings Inc.

Ticker ORGO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 130,888,000
Market Cap $593M
Description
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokin...

More about ORGO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account